bioAffinity Technologies (BIAF) Return on Capital Employed (2022 - 2026)

bioAffinity Technologies (BIAF) has reported Return on Capital Employed for 5 consecutive years, with 184.46% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Capital Employed rose 18399.0% year-over-year to 184.46%; the TTM figure through Mar 2026 stood at 184.46% (up 18399.0% YoY), while the FY2025 annual figure was 181.31%, up 2873.0% from the prior year.
• Return on Capital Employed declined to 184.46% in Q1 2026 per BIAF's latest filing, from 126.66% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.47% in Q4 2022 and bottomed at 392.96% in Q2 2025.
• Historically, Return on Capital Employed has averaged 169.75% across 5 years, with a median of 151.93% in 2024.
• Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 23708 bps — and 2026, when it soared 18399 bps.
• bioAffinity Technologies' Return on Capital Employed stood at 33.47% in 2022, then plunged by 242 bps to 114.6% in 2023, then slumped by 128 bps to 261.19% in 2024, then surged by 52 bps to 126.66% in 2025, then plunged by 46 bps to 184.46% in 2026.
• Business Quant data shows BIAF's Return on Capital Employed at 184.46% in Q1 2026, 126.66% in Q4 2025, and 179.34% in Q3 2025.